ENSC vs. LGVN, ARTL, SNGX, XCUR, THAR, EVOK, GTBP, REVB, ALZN, and PHIO
Should you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include Longeveron (LGVN), Artelo Biosciences (ARTL), Soligenix (SNGX), Exicure (XCUR), Tharimmune (THAR), Evoke Pharma (EVOK), GT Biopharma (GTBP), Revelation Biosciences (REVB), Alzamend Neuro (ALZN), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical preparations" industry.
Ensysce Biosciences (NASDAQ:ENSC) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking.
Ensysce Biosciences has higher revenue and earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.
Longeveron received 4 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. Likewise, 87.50% of users gave Longeveron an outperform vote while only 60.00% of users gave Ensysce Biosciences an outperform vote.
In the previous week, Longeveron had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 2 mentions for Longeveron and 1 mentions for Ensysce Biosciences. Longeveron's average media sentiment score of 0.70 beat Ensysce Biosciences' score of 0.00 indicating that Longeveron is being referred to more favorably in the news media.
5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 39.4% of Ensysce Biosciences shares are owned by company insiders. Comparatively, 24.3% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Ensysce Biosciences has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.
Ensysce Biosciences has a net margin of -476.29% compared to Longeveron's net margin of -3,020.17%. Longeveron's return on equity of -209.14% beat Ensysce Biosciences' return on equity.
Ensysce Biosciences presently has a consensus target price of $7.00, suggesting a potential upside of 1,144.89%. Longeveron has a consensus target price of $12.00, suggesting a potential upside of 622.89%. Given Ensysce Biosciences' higher probable upside, equities analysts clearly believe Ensysce Biosciences is more favorable than Longeveron.
Summary
Ensysce Biosciences and Longeveron tied by winning 8 of the 16 factors compared between the two stocks.
Get Ensysce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ensysce Biosciences Competitors List
Related Companies and Tools
